Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia-Reference-Cited by-同舟云学术

Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia

Published:2020-03 Issue: Volume:472 Page:132-141
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Gupta Pranav^ORCID,Zhang Guan-Nan,Barbuti Anna Maria,Zhang Xin,Karadkhelkar Nishant,Zhou Jingfeng,Ding Ke,Pan Jingxuan,Yoganathan Sabesan,Yang Dong-Hua,Chen Zhe-Sheng

Funder

National Institutes of Health-USA

St. John's University Research Seed Grant

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference50 articles.

1. Cancer statistics, 2018;Siegel;CA A Cancer J. Clin.,2018

2. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC);Zimmermann;Arch. Pharm.,1996

3. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors;Cortes;Blood,2007

4. Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia;Balabanov;Drug Discov. Today Technol.,2014

5. Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells;Shen;Oncotarget,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anticancer Therapy with Proteolysis-targeting Chimeras [PROTACs] Targeting Towards the Tumor-microenvironment: Development, Current State and Prospects;Current Cancer Therapy Reviews;2024-05-14

2. Chemical Derivatization Leads to the Discovery Of Novel Analogs of Azotochelin, a Natural Siderophore, as Promising Anticancer Agents;ChemMedChem;2024-05-14

3. Recent Advances in Signaling Pathways and Kinase Inhibitors for Leukemia Chemotherapy;Current Medicinal Chemistry;2024-02-16

4. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future;Molecules;2022-12-12

5. The progress of small-molecules and degraders against BCR-ABL for the treatment of CML;European Journal of Medicinal Chemistry;2022-08